A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia

Ezimamaka Ajufo, Emil M deGoma, Anna Raper, Kristen Dilzell Yu, Marina Cuchel, Daniel J Rader, Ezimamaka Ajufo, Emil M deGoma, Anna Raper, Kristen Dilzell Yu, Marina Cuchel, Daniel J Rader

Abstract

Purpose: Family-based cascade screening from index probands is considered an effective way of identifying undiagnosed individuals with familial hypercholesterolemia (FH). The role of genetic testing of the proband in the success of cascade screening for FH is unknown.

Methods: We randomized 240 individuals with a clinical diagnosis of FH to genetic testing for FH (n = 160) or usual care with lipid testing alone (n = 80). The primary study endpoint was the proportion of probands with at least one relative enrolled in the study within one year after the notification of results.

Results: Proband median age was 59 (47-67) and 71% were female. Only 28 (12%) probands succeeded in enrolling a relative. While the genetic testing group had a higher proportion of probands with relatives enrolled (13.1%) compared with the usual care group (8.8%), this difference was not significant (p = 0.40). In subgroup analyses, enrollment of a relative was higher in the pathogenic variant group (22.7%) compared to the no pathogenic variant (9.5%) and usual care groups (8.8%) (p = 0.04).

Conclusion: We observed a low rate of family participation in cascade screening despite repeated recommendations to probands. Compared to usual care, genetic testing did not improve family participation in cascade screening for FH.

Clinical trial number: NCT04526457.

© 2021. The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.

References

    1. Abul-Husn, N. S. et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science. (2016).
    1. Benn, M., Watts, G. F., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 97, 3956–3964 (2012).
    1. Mortensen, M. B., Kulenovic, I., Klausen, I. C. & Falk. E. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: prevalence, risk factor burden, and impact on age at presentation. J. Clin. Lipidol. (2016).
    1. De Backer, G. et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis. 241, 169–175 (2015).
    1. Wald, D. S., Bangash, F. A. & Bestwick, J. P. Prevalence of DNA-confirmed familial hypercholesterolaemia in young patients with myocardial infarction. Eur. J. Intern. Med 26, 127–130 (2015).
    1. Pang, J. et al. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J. Clin. Lipidol. 9, 703–708 (2015).
    1. Nordestgaard, B. G. B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur. Heart J. 34, 3478–3490 (2013).
    1. WHO Human Genetics Programme. Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. World Health Organization (1999).
    1. US Centers for Disease Control and Prevention. Office of Public Health Genomics. Genomic tests by levels of evidence. (2016).
    1. Knowles, J. W., Rader, D. J. & Khoury, M. J. Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA. 318, 381–382 (2017).
    1. Sturm, A. C. et al. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. J. Am. Coll. Cardiol. 72, 662–680 (2018).
    1. Umans-Eckenhausen, M. A. W., Defesche, J. C., Sijbrands, E. J. G., Scheerder, R. L. J. M. & Kastelein, J. J. P. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 357, 165–168 (2001).
    1. Umans-Eckenhausen, Ma. W., Defesche, J. C., van Dam, M. J. & Kastelein, J. J. P. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch. Intern. Med. 163, 65–68 (2003).
    1. Leren, T. P., Finborud, T. H., Manshaus, T. E., Ose, L. & Berge, K. E. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 11, 26–35 (2008).
    1. Nherera, L., Marks, D., Minhas, R., Thorogood, M. & Humphries, S. E. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 97, 1175–1181 (2011).
    1. Degoma, E. M. et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States. Circ. Cardiovasc. Genet. 9, 240–249 (2016).
    1. McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M. & Duell, P. B. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J. Am. Heart Assoc. (2019).
    1. Johns, M. B. & Paulus-Thomas, J. E. Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol. Anal. Biochem. 180, 276–278 (1989).
    1. Maglio, C. et al. Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J. Intern. Med. 276, 396–403 (2014).
    1. GRIFOLS. FH genetic testing. (2020).
    1. Lee, C., Rivera-Valerio, M., Bangash, H., Prokop, L. & Kullo, I. J. New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature. Circ. Genomic Precis. Med. 12, e002723 (2019).
    1. Senior, V., Marteau, T. M. & Weinman, J. Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions. Cardiovasc. Drugs Ther. 18, 475–481 (2004).
    1. Marteau, T. et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am. J. Med. Genet. A 128A, 285–293 (2004).
    1. Hardcastle, S. J. et al. Patients’ perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int. J. Behav. Med. 22, 92–100 (2015).
    1. Hallowell, N. et al. Patients’ experiences and views of cascade screening for familial hypercholesterolemia (FH): a qualitative study. J. Community Genet. 2, 249–257 (2011).
    1. Damgaard, D. et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 180, 155–160 (2005).
    1. Shin, D. G. et al. Clinical features of familial hypercholesterolemia in Korea: predictors of pathogenic mutations and coronary artery disease—a study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis. 243, 53–58 (2015).
    1. Civeira, F. et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am. J. Cardiol. 102, 1187–93, 1193.e1 (2008).
    1. Chora, J. R., Medeiros, A. M., Alves, A. C. & Bourbon, M. Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis. Genet. Med. 20, 591–598 (2018).
    1. Khera, A. V. et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67, 2578–2589 (2016).
    1. Louter, L., Defesche, J. & Roeters van Lennep, J. Cascade screening for familial hypercholesterolemia: practical consequences. Atheroscler. Suppl. 30, 77–85 (2017).
    1. Caswell-Jin, J. L. et al. Cascade genetic testing of relatives for hereditary cancer risk: results of an online initiative. J. Natl. Cancer Inst. 111, djy147 (2019).
    1. Van Maarle, M. C. et al. How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia?: psychological impact and screenees’ views. Community Genet. 4, 244–252 (2001).
    1. Newson, A. J. & Humphries, S. E. Cascade testing in familial hypercholesterolaemia: How should family members be contacted? Eur. J. Hum. Genet. 13, 401–408 (2005).

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe